Resistant Hypertension and Cardiorenovascular Risk
BANTAO Journal · 2017
DOI: 10.1515/bj-2017-0002 ↗Kurz gefasst
Fachartikel in der Zeitschrift BANTAO Journal, 2017. Verfasst von Ingrid Prkacin und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Studies have documented independent contribution of sympathetic activation to the cardiovascular disease continuum. Hypertension is one of the leading modifiable factors. Most if not all the benefit of antihypertensive treatment depends on blood pressure lowering, regardless how it is obtained. Resistant hypertension is defined as blood pressure that remains uncontrolled in spite of the concurrent use of three antihypertensive drugs of different classes. Ideally, one of the three drugs should be a diuretic, and all drugs should be prescribed at optimal dose amounts. Poor adherence to antihypertensive therapy, undiscovered secondary causes (e.g. obstructive sleep apnea, primary aldosteronism, renal artery stenosis), and lifestyle factors (e.g. obesity, excessive sodium intake, heavy alcohol intake, various drug interactions) are the most common causes of resistant hypertension. Cardio(reno)vascular morbidity and mortality are significantly higher in resistant hypertensive than in general hypertensive population, as such patients are typically presented with a long-standing history of poorly controlled hypertension. Early diagnosis and treatment is needed to avoid further end-organ damage to prevent cardiorenovascular remodeling. Treatment strategy includes lifestyle changes, adding a mineralocorticoid receptor antagonist, treatment adherence in cardiovascular prevention and, in case of failure to control blood pressure, renal sympathetic denervation or baroreceptor activation therapy. The comparative outcomes in resistant hypertension deserve better understanding. In this review, the most current approaches to resistant hypertension and cardiovascular risk based on the available literature evidence will be discussed.
Zitieren
APA
Prkacin, I., Vrdoljak, P., Cavric, G., Vazanic, D., Pervan, P., & Adam, V. (2017). Resistant Hypertension and Cardiorenovascular Risk. BANTAO Journal. https://doi.org/10.1515/bj-2017-0002
Vancouver
Prkacin I, Vrdoljak P, Cavric G, Vazanic D, Pervan P, Adam V. Resistant Hypertension and Cardiorenovascular Risk. BANTAO Journal. 2017. doi:10.1515/bj-2017-0002
BibTeX
@article{Prkacin2017,
author = {Prkacin, Ingrid and Vrdoljak, Petra and Cavric, Gordana and Vazanic, Damir and Pervan, Petra and Adam, Visnja-Nesek},
title = {Resistant Hypertension and Cardiorenovascular Risk},
journal = {BANTAO Journal},
year = {2017},
doi = {10.1515/bj-2017-0002}
}
EUVIMED